Mounjaro®
Starting from £179.99/mo
Start journey Learn moreTaking Mounjaro for only two months is possible, but two months is rarely enough time to see the full picture. Mounjaro is a prescription-only medicine licensed for ongoing weight management in adults, and the first four to eight weeks are largely a tolerability period as your body adjusts to the starting dose. That means most of the weight-management benefit comes later, not in the first two months. Whether a shorter course makes sense for you is a clinical question your prescriber needs to answer based on your health, your goals, and how you respond to treatment — not something that can be decided in advance of starting. These are prescription-only medicines assessed individually; no single timeline fits everyone.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The starting dose of Mounjaro is 2.5 mg. Its job is to let your digestive system adjust gradually, nausea and other gastrointestinal effects are most likely to appear early, and beginning low reduces that risk significantly. Most prescribers move to 5 mg after four weeks if the lower dose is well tolerated.
So after two months, many people are only just reaching their first full therapeutic dose. The appetite-reducing effect does build during this period, and some weight loss is common, but the licensed treatment programme is designed to continue well beyond that point. Clinical trials in the SURMOUNT programme followed participants for 72 weeks (roughly 17 months) which is the basis for the efficacy figures cited by NICE in their appraisal of tirzepatide (TA1026). Two months represents roughly 11% of that trial window.
That context does not mean a short course is useless. It means going in with accurate expectations matters. Some people do use Mounjaro for a defined period (ahead of a surgical procedure, for example, or during a specific health intervention) and then stop with their prescriber's guidance. That is different from stopping because the first two months felt slow.
If you want a broader overview of how tirzepatide works and what the evidence shows, the Mounjaro information page covers the mechanism and trial data in full.
The question of duration is really three separate questions rolled into one, and separating them helps.
How much weight do you want to lose, and how quickly? If the goal is modest (say, 5–8% of body weight to bring blood pressure into range before a review appointment) two months at lower doses might contribute meaningfully, even if it is not the full course. If the goal is more substantial, two months is almost certainly a partial step rather than a complete one.
What happens when you stop? This is the part that catches people off guard. Mounjaro reduces appetite while you take it; the appetite suppression does not persist after you stop. Without the lifestyle changes that should run alongside treatment, weight often returns. The NHS tirzepatide information page is clear that this medicine is intended to be used alongside a reduced-calorie diet and increased physical activity, not instead of them. Building those habits during the treatment window is what makes a shorter course more durable.
What is your reason for a time limit? Cost, a holiday, a planned pregnancy, a surgery date, personal preference, each has a different clinical implication. Some of these are good reasons to plan a pause; others might resolve differently once you have talked them through. Our clinical team works through exactly these scenarios with patients at every review.
Studies on GLP-1 and dual-agonist medicines consistently show that a significant proportion of the weight lost during treatment returns after stopping, particularly without structured lifestyle support in place. This is not a failure of willpower; it reflects the biological role these medicines play in appetite regulation.
That does not mean stopping is wrong. It means stopping well, with a plan, is very different from stopping abruptly because the first few months felt underwhelming. If you are considering a short course partly because of the cost involved, it is worth reading about what is included in treatment pricing before deciding, the Mounjaro cost page breaks this down honestly, including what a single transparent price at a regulated pharmacy covers.
If you are thinking about stopping because you are not sure whether you qualify long-term, that is a separate conversation. Eligibility for Mounjaro is assessed on your BMI and health history at consultation, it is not tied to a fixed treatment duration. And if you have already paused and are wondering whether a one-month restart makes sense, our page on whether you can take Mounjaro for just one month covers that specific scenario in detail.
Because nume does not use subscriptions or auto-renewals, every repeat order is a fresh clinical decision. You could, in principle, order for one or two months and then stop, your prescriber reviews your case before each dispatch, and nothing continues without your consent and theirs.
The practical reality, though, is that timing does matter. Orders placed by 12pm on a working day are dispatched the same day once clinically approved, arriving via DPD the next working day. If you are planning a two-month window around, say, a holiday or a specific appointment, naming that clearly in your consultation helps the prescriber give you the most useful guidance for your timeline.
What does not change with a shorter intended course is the clinical assessment itself. Whether Mounjaro is appropriate for you at all (regardless of how long you plan to take it) is determined by a GPhC-registered prescriber reviewing your health information, weight, and medical history. That step happens every time, and it is the step that keeps short courses safe rather than speculative.
If you are ready to have that conversation, speak to our prescribers through a free consultation at our treatment page.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.